Berenberg Bank set a €145.00 ($168.60) price objective on MorphoSys (ETR:MOR) in a research report sent to investors on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
MOR has been the topic of a number of other reports. Independent Research set a €110.00 ($127.91) price target on shares of MorphoSys and gave the stock a neutral rating in a research report on Friday, November 1st. Royal Bank of Canada set a €130.00 ($151.16) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. set a €130.00 ($151.16) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Wednesday, October 30th. HSBC set a €81.00 ($94.19) price target on shares of MorphoSys and gave the stock a sell rating in a research report on Friday, August 16th. Finally, Deutsche Bank set a €129.00 ($150.00) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of €118.00 ($137.21).
Shares of ETR MOR opened at €94.65 ($110.06) on Monday. The firm has a market cap of $3.00 billion and a price-to-earnings ratio of -31.11. MorphoSys has a 52-week low of €79.70 ($92.67) and a 52-week high of €114.70 ($133.37). The company’s 50-day simple moving average is €99.17 and its 200-day simple moving average is €97.19. The company has a quick ratio of 7.63, a current ratio of 7.80 and a debt-to-equity ratio of 9.78.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.